These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. Lewczuk P; Esselmann H; Groemer TW; Bibl M; Maler JM; Steinacker P; Otto M; Kornhuber J; Wiltfang J Biol Psychiatry; 2004 Mar; 55(5):524-30. PubMed ID: 15023581 [TBL] [Abstract][Full Text] [Related]
4. Relevance of defensin β-2 and α defensins (HNP1-3) in Alzheimer's disease. Szekeres M; Ivitz E; Datki Z; Kálmán J; Pákáski M; Várhelyi ZP; Klivényi P; Zadori D; Somogyvári F; Szolnoki Z; Vécsei L; Mándi Y Psychiatry Res; 2016 May; 239():342-5. PubMed ID: 27082275 [TBL] [Abstract][Full Text] [Related]
5. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. Lui JK; Laws SM; Li QX; Villemagne VL; Ames D; Brown B; Bush AI; De Ruyck K; Dromey J; Ellis KA; Faux NG; Foster J; Fowler C; Gupta V; Hudson P; Laughton K; Masters CL; Pertile K; Rembach A; Rimajova M; Rodrigues M; Rowe CC; Rumble R; Szoeke C; Taddei K; Taddei T; Trounson B; Ward V; Martins RN; AIBL Research Group J Alzheimers Dis; 2010; 20(4):1233-42. PubMed ID: 20413897 [TBL] [Abstract][Full Text] [Related]
6. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls. Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805 [TBL] [Abstract][Full Text] [Related]
7. The amyloid-β degradation pattern in plasma--a possible tool for clinical trials in Alzheimer's disease. Pannee J; Törnqvist U; Westerlund A; Ingelsson M; Lannfelt L; Brinkmalm G; Persson R; Gobom J; Svensson J; Johansson P; Zetterberg H; Blennow K; Portelius E Neurosci Lett; 2014 Jun; 573():7-12. PubMed ID: 24796810 [TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251 [TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein C-III is an amyloid-β-binding protein and an early marker for Alzheimer's disease. Shih YH; Tsai KJ; Lee CW; Shiesh SC; Chen WT; Pai MC; Kuo YM J Alzheimers Dis; 2014; 41(3):855-65. PubMed ID: 24685634 [TBL] [Abstract][Full Text] [Related]
10. Brain amyloid-beta fragment signatures in pathological ageing and Alzheimer's disease by hybrid immunoprecipitation mass spectrometry. Portelius E; Lashley T; Westerlund A; Persson R; Fox NC; Blennow K; Revesz T; Zetterberg H Neurodegener Dis; 2015; 15(1):50-7. PubMed ID: 25591542 [TBL] [Abstract][Full Text] [Related]
14. Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: an update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study. Ellis KA; Rainey-Smith SR; Rembach A; Macaulay SL; Villemagne VL; Int Rev Psychiatry; 2013 Dec; 25(6):699-710. PubMed ID: 24423223 [TBL] [Abstract][Full Text] [Related]
15. Identification of novel APP/Abeta isoforms in human cerebrospinal fluid. Portelius E; Brinkmalm G; Tran AJ; Zetterberg H; Westman-Brinkmalm A; Blennow K Neurodegener Dis; 2009; 6(3):87-94. PubMed ID: 19229112 [TBL] [Abstract][Full Text] [Related]
16. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. Hansson SF; Andréasson U; Wall M; Skoog I; Andreasen N; Wallin A; Zetterberg H; Blennow K J Alzheimers Dis; 2009; 16(2):389-97. PubMed ID: 19221428 [TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758 [TBL] [Abstract][Full Text] [Related]
18. Effects of Alzheimer's disease-associated risk loci on cerebrospinal fluid biomarkers and disease progression: a polygenic risk score approach. Martiskainen H; Helisalmi S; Viswanathan J; Kurki M; Hall A; Herukka SK; Sarajärvi T; Natunen T; Kurkinen KM; Huovinen J; Mäkinen P; Laitinen M; Koivisto AM; Mattila KM; Lehtimäki T; Remes AM; Leinonen V; Haapasalo A; Soininen H; Hiltunen M J Alzheimers Dis; 2015; 43(2):565-73. PubMed ID: 25096612 [TBL] [Abstract][Full Text] [Related]
19. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment. DeKosky ST; Ikonomovic MD; Wang X; Farlow M; Wisniewski S; Lopez OL; Becker JT; Saxton J; Klunk WE; Sweet R; Kaufer DI; Kamboh MI Ann Neurol; 2003 Jan; 53(1):81-90. PubMed ID: 12509851 [TBL] [Abstract][Full Text] [Related]